Tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC): • who are considered cisplatin ineligible, and whose tumours have a PD-L1 expression ≥5% (see section 5.1). Tecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours have PD-L1 expression ≥1% and who have not received prior chemotherapy for metastatic disease. The gene discussed is CD274; the disease is neoplasm.